iCardiac Has Been Acquired by ERT
December 6, 2017
iCardiac Technologies, an industry-leading centralized core laboratory for clinical trial services and a portfolio company of Norwest Venture Partners, has been acquired by ERT.
Cain Brothers served as iCardiac’s financial advisor in connection with the transaction.
Headquartered in Rochester, NY, iCardiac is a leading centralized core laboratory for cardiac safety, respiratory, and eCOA clinical trial services. The company’s sophisticated, algorithm-driven technology, which supports efficient, cost-effective, and regulatory-compliant methods of conducting cardiac assessments, will expand ERT’s portfolio of cardiac safety solutions. iCardiac serves eight of the top 10 global pharmaceutical companies, as well as numerous small and mid-sized pharma and biotechnology firms.
Norwest is a leading Silicon-Valley based venture capital and growth equity investment firm managing more than $6 billion in capital. Since its inception, the firm has invested in more than 600 companies.
ERT is a global data and technology company that minimizes uncertainty and risk in clinical trials. Since 2014, more than half of all FDA drug approvals came from ERT-supported studies. Pharma companies, biotechs and CROs have relied on ERT solutions in 10,000+ studies, spanning over three million patients to date.